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Background: The human immune proteins APOBEC3G and APOBEC3F (hA3G and hA3F) induce destructive G-to-A
changes in the HIV genome, referred to as ‘hypermutation’. These two proteins co-express in human cells,
co-localize to mRNA processing bodies and might co-package into HIV virions. Therefore they are expected to also
co-mutate the HIV genome. Here we investigate the mutational footprints of hA3G and hA3F in a large population
of full genome HIV-1 sequences from naturally infected patients to uniquely identify sequences hypermutated by
either or both of these proteins. We develop a method of identification based on the representation of hA3G and
hA3F target and product motifs that does not require an alignment to a parental/consensus sequence.
Results: Out of nearly 100 hypermutated HIV-1 sequences only one sequence from the HIV-1 outlier group showed
clear signatures of co-mutation by both proteins. The remaining sequences were affected by either hA3G or hA3F.
Conclusion: Using a novel method of identification of HIV sequences hypermutated by the hA3G and hA3F
enzymes, we report a very low rate of co-mutation of full-length HIV sequences, and discuss the potential
mechanisms underlying this.
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Human apolipoprotein B mRNA-editing enzyme, cata-
lytic polypeptide-like 3G and 3F (hA3G,F) are enzymes
important in the control of viral growth [1,2]. They are
known for their ability to block HIV infection in the
absence of the virion infectivity factor (Vif ) [3]. The
mechanisms of inhibition proposed for these proteins can
be classified as either cytosine deamination-dependent [4]
or deamination-independent [5]. In the former, one or
more hA3G and/or hA3F molecules are trafficked into a
nascent virion and are released along with the viral RNA
into the cytoplasm of a newly infected cell. The HIV RNA
is reverse transcribed in the host cell to create a DNA
minus strand followed by degradation of the original RNA
and its replacement by a DNA plus strand. During the
degradation of the viral RNA, regions of the DNA minus
strand remain transiently unpaired. These single stranded
DNA regions are targeted by hA3G and/or hA3F [6].
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reproduction in any medium, provided the orsequence motifs. For example hA3G and hA3F preferen-
tially target C within the context of CC and TC, respect-
ively (the underlined cytosine is deaminated to uracil).
The uracils in the minus strand pair with adenosines in
the plus strand. Therefore the action of hA3G, F results in
the replacement of G by A in the plus strand and subse-
quently in the HIV RNA genome. The G-to-A mutation
hotspots are GG and GA for hA3G and hA3F, respectively
[7,8]. Usually the HIV sequences targeted by these
enzymes show G-to-A mutations in multiple positions;
therefore are referred to as hypermutated sequences [9].
It is known that hA3G and hA3F are widely co-
expressed in the human cells [10,11] and co-localize in
the mRNA processing (P) bodies [12]. They might also
co-package into nascent HIV virions, thus acting co-
operatively to inhibit HIV infection [10,11]. Despite this,
most of the studies so far have concentrated on the im-
pact of individual APOBEC3 proteins. Therefore, the
collective impact of these proteins on the HIV genome is
not clear. The limited studies of the effect of both pro-
teins have returned contradicting results. Analysis of
hypermutated sequences from the HIV-1 pol [13], vpu/al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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genomes [16] points to the substantial domination of ei-
ther hA3G or hA3F. However, lightly mutated sequences
with footprints of both proteins have also been reported
[14]. In addition, analysis of fractional env/nef [17] and
in a different study, vif, gag and env [18] have shown
sequences with mutations within both GG and GA
motifs. However, given short sequence reads and the
limitations of current identification methods, it can often
be hard to identify the target motif preferences of hyper-
mutation. The aim of this study is to find out what pro-
portion of the in vivo full genome HIV sequences are
targeted by both proteins. To achieve this aim the first
step is to accurately identify sequences that contain sig-
natures of mutation by hA3G and/or hA3F [7,19]. To in-
vestigate the joint impact of hA3G and hA3F, we
developed a method that identifies sequences hypermu-
tated by hA3G, hA3F or both by taking advantage of the
unique context-dependency of G-to-A mutation by
hA3G and hA3F. The target motifs GG (for hA3G) and
GA (for hA3F) are less represented in the genomes of
hypermutated sequences compared to those of normal
HIV sequences. By contrast, the product motifs (AG and
AA) are more represented in the hypermutated
sequences compared to normal sequences. Therefore,
a measure of ‘motif representation’ [20] can be used
to identify affected sequences. It is worth noting that
all hA3 proteins, except for hA3G, have a dinucleotide
target preference similar to that of hA3F [21]. There-
fore, any signature attributed to hA3F in this paper
could well be the footprint of other hA3 proteins with
a GA-to-AA mutation preference. The reason for the
use of hA3F here is its greater mutagenic activity
against HIV when compared to the other hA3 members
with the same motif preference.
Here, we calculate the representation of hA3G and
hA3F target and product motifs in 2829 HIV-1 sequences
as well as in the 88 full genome HIV-1 sequences classi-
fied as “hypermutated” in the Los Alamos National
Laboratory (LANL) database. These 2917 sequences are
from all groups (M, O, N and P), subtypes (A, B, C, D, F,
G, H, J and K) and recombinant forms (e.g. 01_AE, A1D,
A2C, A1DK, A1A2D, 21_A2D, 02_AG, 04_cpx, 05_DF,
BF and the like) that have been reported in the database.
The results showed only one sequence, out of approxi-
mately one hundred hypermutated sequences, with clear
signatures of mutation by both hA3G and hA3F. Interest-
ingly this sequence does not belong to any of the sub-
types and recombinant forms of the HIV main (M) group
and has been classified as an outlier (O) HIV-1 sequence.
Analysis of in vitro hypermutated sequences as well as
simulated hypermutation data further confirmed the effi-
ciency of the method based on motif representation in
identification of co-mutated sequences.Results
Identification of hypermutated sequences
The Hotelling’s T2 statistics of the HIV-1 sequences are
shown in Figure 1. In this figure, the 2829 sequences
that are “normal” according to the LANL database ap-
pear first on the horizontal axes (shown by black circles)
followed by the 88 sequences identified by LANL as
“hypermutated” (shown by red triangles). Figure 1a)
shows all the sequences and Figure 1b) the lower range
of T2 axis (T2<60) that covers all the nominally normal
HIV-1 sequences and some of hypermutated sequences.
As indicated, compared to normal HIV-1 sequences, the
hypermutated sequences exhibit larger T2 values (up to
over 800 times larger). The 95%, 99% and 99.9% confi-
dence interval of the Hotelling’s T2 are the values 6.00,
9.23 and 13.85, respectively. Figure 1b shows 7 sequen-
ces indicated by filled circles (see Table 1), that are
different from the population of normal sequences at
confidence levels (α) >> 99.9%. The high significance
levels of these sequences may imply that they are hyper-
mutated sequences which have been misclassified as nor-
mal in the database.
Among those sequences tagged as hypermutated in
LANL database, we identified two sequences (shown by
filled triangles under the 95% confidence interval line in
Figure 1b) that are different from the population of nor-
mal HIV-1 sequences at confidence levels less than 50%.
This may imply that these two sequences are normal
HIV-1 sequences which have been misclassified as
hypermutated in the database. Another explanation
could be that these are lightly mutated sequences for
which it is not possible to discriminate random G-to-A
mutation (by reverse transcriptase) [22] from context
dependent G-to-A mutation (by hA3G,F) within a large
population of HIV sequences. Therefore, they appear
within the range of normal HIV-1 sequences. Table 1
shows the accession numbers of the sequences for which
we estimate a hypermutation status different from those
of the LANL database.
Identification of source of hypermutation
In order to identify which protein (hA3G, hA3F or both)
is responsible for hypermutating the HIV sequences a
plot of DRhA3G versus DRhA3F (Figure 2) is used here. In
this figure the nominally normal and hypermutated
sequences are shown by circles and triangles, respect-
ively. The nominally normal sequences with T2 >13.85
which lie outside the 99.9% confidence interval (broken
line) are shown by filled circles. The two nominally
hypermutated sequence which are very similar to normal
sequences (α<50%) are shown by filled triangles. As indi-
cated the normal HIV-1 sequences form a tight cluster
around ratios at DRhA3G =1 and DRhA3F =1. In this
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Figure 1 The Hotelling’s T2 statistics of HIV-1 sequences. There are in total 2917 full genome (> 7000 n.t.) HIV-1 sequences including 2829
nominally normal and 88 nominally hypermutated sequences. The hypermutated sequences are from no. 2830-2917 on the horizontal axis. The
filled circles are the nominally normal sequences which are significantly different from the normal HIV-1 population at >> 99.9% confidence
levels, thus appear to be hypermutated. The filled triangles are the nominally hypermutated sequences that are significantly different from the
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ably due to a general G-to-A mutation error by the HIV
reverse transcriptase. This dependency is significantly
reduced in the hypermutated sequences in which the G-
to-A mutation is motif dependent and different for
hA3G and hA3F. These unique features of Figure 2 en-
able one to identify source(s) of hypermutation.
The following points can be inferred from this figure:



















The hypermutated sequences are classified into three
categories shown by filled arrows. The first categorye 1 A list of seven HIV-1 sequences with α>> 99.9%
two HIV-1 sequences with α < 50%
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Figure 2 The plot of DRhA3G versus DRhA3F of 2917 full genome
(>7000 n.t.) HIV-1 sequences. The sequences identified as normal
and hypermutated by LANL are shown using black circles and red
triangles, respectively. The seven nominally normal sequences with
α >> 99.9% (appear outside the 99.9% confidence interval broken
line) are shown by filled circles. The two nominally hypermutated
sequences with α < 50% are shown by filled triangles. The
sequences hypermutated by hA3G appear along the horizontal axis
and those affected by hA3F extend along the vertical axis. The
sequences co-mutated by hA3G and hA3F locate between these
two groups.
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appear along the horizontal axis. These sequences
show signs of mutation by hA3G. The second
category contains sequences with a high DRhA3F
which stretch along the vertical axis. These
sequences have footprints of mutation by hA3F. The
third category includes sequences which are high in
both DRhA3G and DRhA3F. These sequences which have
footprints of co-mutation by hA3G and hA3F would
appear in the top right quarter of the graph. The
sequence shown by number “1” is from this category.
In Figure 2 seven nominally normal sequences with
α >>99.9% are shown with filled circles. Two of these
sequences extend in the direction of mutation by
hA3G and four in the direction of the hA3F axis,
implying that they are hypermutated sequences.
There is one sequence (shown by a small arrow) that
appears outside the 99.9% interval but does not
extend in either direction.2- Extent of hypermutation
Within the reported sequences in the database, the
number of sequences targeted by hA3G is much
larger than those affected by hA3F. The extent of
hypermutation by hA3G is also greater than that of
hA3F as evidenced by the larger scale of the DRhA3G
axis compared to that of DRhA3F. The calculated
values of DRhA3G and DRhA3F can be used as a
measure of the extent of mutation. In general the
larger these values the more mutation the sequence
has undergone.3- Mutation by both hA3G and hA3F
The sequences which are mutated by both hA3G
and hA3F would be located away from the normal
sequences and between the sequences targeted by
either hA3G or hA3F. The contribution of each
protein in hypermutation can be determined from
the location of the targeted sequence in the space of
DRhA3G versus DRhA3F. Surprisingly only one
sequence, shown by “1” and belonging to the outlier
HIV group, exhibits a clear footprint of both
proteins. However it is located closer to the line of
hypermutated sequences by hA3G indicating a
greater contribution from hA3G. This sequence
(accession number AF407419) was isolated from an
HIV patient in 1992 and contains multiple stop
codons in all open reading frames. There are also
two other sequences (shown by numbers 2 and 3)
with slightly elevated DRhA3F values compared to
those of the remaining sequences mutated by hA3G.
Within the HIV-1 sequences, there is no extensively
co-hypermutated sequence with an equal or greater
contribution from hA3F. A list of hypermutatedsequences at >99.9% confidence level, their accession
numbers and source(s) of mutation is given in the
Additional file 1: Table S1.Analysis of negative strands
Our analysis suggests that motif representation is a use-
ful method for classifying HIV sequences as hypermu-
tated. However, it is also possible that the variations in
motif representation we observe arose by random
chance, or non-specific mutation. Since these processes
are expected to affect the positive and negative HIV
strands equally, whereas hypermutation should show its
signature only on the positive strand, we therefore ana-
lysed the motif representation of the negative strands.
Consistent with a strand-specific mechanism of muta-
tion, the motif ratios of the negative strands clustered
much more evenly than the positive strands, with no
clear evidence for context-dependent mutation. We note
also that issues such as codon usage or conserved regu-
latory elements that may bias motifs should be equally
present in negative strands [using the complement of
the motif]. This confirms the utility of our method and
that it is not excessively biased by these factors. The
results are given in Figure S2 of the Additional file 1.
In vitro hypermutation
In order to confirm the efficacy of the proposed method
in identifying co-mutated sequences we analysed a data
set consisting of 19 clade B HIV-1 sequences that have
been hypermutated in vitro by either hA3G or hA3F [7].
This data set does not contain any co-mutated sequence;
ten of these sequences have been hypermutated by hA3G,
and nine by hA3F (see reference [7] for details). Thus the
analysis is expected not to return any HIV-1 sequences
with elevated DRhA3G and DRhA3F. This is expected to be
characterized by an empty space between the axes DRhA3G
and DRhA3F in a plot similar to Figure 2. The results of the
analysis of these sequences are shown in Figure 3 and
Table 2. In Figure 3 the non-hypermutated consensus se-
quence is shown by a triangle and the hA3G and hA3F
hypermutated sequences by open and closed rhombuses,
respectively. The pattern displayed in this figure is very
similar to the pattern of in vivo sequences shown in
Figure 2. The in vitro sequences hypermutated by hA3G
lie on the right hand side of the consensus sequence and
extend along the horizontal axes depending on their level
of hypermutation. The in vitro hypermutated sequences
by hA3F locate on the left hand side of the consensus se-
quence and extend along the vertical axis. The hypermu-
tated HIV-1 sequences (except for two lightly mutated by
hA3F) were identified at very high confidence levels (α >>
99.9%). Importantly, no sequence was located in the area
between the hA3G and hA3F hypermutated sequence that














Figure 3 The plot of DRhA3G versus DRhA3F of a consensus
HIV-1 sequence and 19 sequences hypermutated by either
hA3G or hA3F. The consensus sequence is shown using a red
triangle. Hypermutated sequences by hA3G or hA3F are shown
using open and closed rhombuses, respectively. The 99.9%
confidence interval of the subtype B HIV-1 population is shown by
an oval. The sequences hypermutated by hA3G appear along the
horizontal axis, and those hypermutated by hA3F extend along the
vertical axis. There is no co-mutated sequence in this dataset.
Table 2 The accession numbers, DRs, T2 values and
hypermutation status of the HIV-1 sequences
hypermutated in vitro by hA3G (sequences starting with
3G) or hA3F (sequences starting with 3F)
Sequence DRhA3F DRhA3G T
2 α > 99.9%
consensus 0.96 1.03 1.85
3G6 0.89 1.43 190.90 √
3G7 0.90 1.69 559.86 √
3G8 0.92 1.17 28.32 √
3G33 0.88 1.47 224.16 √
3G40 0.90 1.31 98.47 √
3G72 0.91 1.20 39.09 √
3G105 0.89 1.42 182.50 √
3G108 0.89 1.32 103.49 √
3G111 0.90 1.31 98.75 √
3G113 0.90 1.43 200.02 √
3F11 1.01 1.00 3.69 ×
3F14 1.16 0.94 79.28 √
3F18 1.25 0.86 152.79 √
3F41 1.12 0.95 46.12 √
3F52 1.06 0.96 14.27 √
3F114 0.98 1.00 0.20 ×
3F116 1.13 0.94 53.23 √
3F117 1.12 0.95 40.87 √
3F124 1.14 0.94 59.93 √
√: Identified with high confidence ×: Not identified with high confidence.
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Since neither the analysis of patient sequences from the
database nor in vitro hypermutated sequences identified
co-mutated genomes, this raises the question of whether
our method can detect co-mutated sequences if they
occur. In the absence of experimental sequences that ap-
pear co-mutated, we simulated co-mutation as described
below.
We used the normal complete genome HIV-1 popula-
tion described earlier and randomly mutated 20-200 G
nucleotides to A nucleotides either within GG (for
hA3G) or within GA (for hA3F), or within both motifs
together. For comparison we also performed, in a separ-
ate simulation, context-independent (random) G-to-A
changes to mimic the effect of reverse transcriptase. The
results are shown in Figure 4. As expected the direction
of the extension of the HIV sequences in Figure 4 is very
similar to those of in vivo sequences shown in Figure 2.
Mutation by either hA3G or hA3F led to the spread of
sequences along the respective axes. When both motifs
were targeted by mutation, co-mutated HIV sequences
filled the space between the two axes DRhA3G and
DRhA3F as expected, whereas this space is almost empty
for the in vivo data.
The motif dependent G-to-A changes by hA3G and/or
hA3F results in an increase in DRhA3G and/or DRhA3F,
However, random G-to-A changes by reverse transcript-
ase do not affect these two diagnostic ratios. As a result
the HIV population generated by a random (context-in-
dependent) G-to-A mutation simulation does not differ
from the original HIV population (see panels A and E of
Figure 4). The results of the analysis of the simulation
data imply that co-mutation by hA3G and hA3F is de-
tectable if present and that its absence from the in vivo
sequences suggests it is a rare event.
Discussion
The proteins hA3G and hA3F are important enzymes in
controlling viral replication. One of their mechanisms of
action is the introduction of multiple mutations into the
genome of the affected viruses. The genes for these two
proteins are located in close proximity on chromosome
22. They are widely co-expressed in different tissues and
also co-packaged into the HIV virions. This may indicate
that hA3G and hA3F act cooperatively against HIV.
There are many reports on the mutagenicity of each of
these individual proteins, but their co-operative action is
less understood [11]. This may be partly due to the ana-
lysis of short sequences (typically < 10% of the complete
HIV genome) [11,13-15,17,23] within which it is not
trivial to accurately identify mono- versus co-mutated
signatures. Also the previous method of identification
has usually been based on alignment and comparison of




Figure 4 The plot of DRhA3G versus DRhA3F for A) normal HIV-1 population and simulated mutations by B) both hA3G & hA3F
(GG-to-AG & GA-to-AA), C) hA3G (GG-to-AG), D) hA3F (GA-to-AA) and E) reverse transcriptase (random G-to-A).
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quence of hypermutated sequences. Here, we studied
the cooperative impact of hA3G and hA3F by investigat-
ing the mutation footprint they have left on the full gen-
ome hypermutated HIV sequences. We developed a
novel bioinformatics approach for accurate identification
of sequences hypermutated by either or both of
these two enzymes. Identification of hypermutated
sequences is important as they contain information
about the mutation mechanism by hA3G and hA3F.
Our method identifies hypermutated HIV-1 sequences
using the within sequence signature(s) of G-to-A
changes by hA3G and/or hA3F. It also uniquelydiscriminates among G-to-A mutation by reverse tran-
scriptase, hA3G, hA3F and both of these latter pro-
teins. It is based on the representation of hA3G and
hA3F target and product motifs in the genome of thou-
sands of HIV sequences. The representation of each
motif is quantified in such a way that it becomes inde-
pendent of the frequency of its constituent mononu-
cleotides. We have coded the algorithm into an executable
Java program ‘hypersign’ that is available as an Additional
file 2. Analysis of a large population of full genome HIV-1
sequences revealed that co-mutation of the same genome
by hA3G and hA3F is a rare event. We performed simula-
tions to confirm that co-mutation is detectable by
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of the analytic approach.
Two possible mechanisms can be postulated to explain
the rarity of co-mutated sequences. Firstly, a low propor-
tion of total sequences showing any hypermutation was
observed, suggesting very few virions incorporate APO-
BEC3 proteins [24]. This could either arise because most
virions have no co-packaged APOBEC3, but a few virions
package one and some co-package two copies of the
enzymes. In this scenario, it is easy to imagine that the
number of copies of APOBEC3 should be Poisson distrib-
uted. So, assuming random sampling, if 12 out of 2917
genomes (see Figure 2) have at least one hA3F protein and
79 out of 2917 have at least one hA3G, then we would
only expect 1×10-4 virions having at least one copy of each
enzyme. Thus, given the small number of total sequences
showing hypermutation, the low frequency of co-mutated
sequences maybe explained simply by the low chance of
incorporation of either enzyme individually.
Alternatively, hypermutation may arise because Vif
fails to exert its effects in a small proportion of cells,
leading to co-packaging of many copies of APOBEC3
into the genomes produced from these cells. In this case,
we might expect that many genomes that contain either
hA3G or hA3F would in fact have copies of both
enzymes. In this case, then the lack of co-mutation may
suggest either that these two proteins compete for the
same HIV RNA, or that co-packaged hA3G and hA3F
interfere with the enzymatic activity of one another, per-
haps by forming hetero-oligomers [10-12]. An alterna-
tive possibility is that, in the presence of co-packaged
hA3G and hA3F, one enzyme acting before the other
may somehow disrupt the target motifs or inhibit our
ability to recognize co-mutation. However, we have
simulated these enzymes acting in different orders, and
find this does not significantly affect the ability to
recognize co-mutated sequences (data not shown); there-
fore this seems to be an unlikely explanation.
Conclusion
Our analysis clearly illustrates that co-mutation by
hA3G and hA3F is a rare occurrence. However, we are
unable to draw conclusions as to the biological mechan-
isms behind this. Further sequencing of full-length HIV
genomes derived from in vivo infection might help iden-
tify if the frequency of co-mutation is consistent with a
Poisson distribution of hA3G and hA3F singly mutated
genomes. However, our estimates are that this would re-
quire a large number of sequences to accurately estimate
this frequency. Alternatively, experimental approaches to
determine the accurate stoichiometry of hA3 molecules
per virion in vivo might also identify whether a low fre-
quency of incorporation and low copy number of incor-
porated enzymes is present.Methods
In order to distinguish hypermutated from normal
sequences a measure of the representation of hA3G and
hA3F target and product motifs is required. The “repre-
sentation” of a motif needs to be a quantity that signifies
the difference between the observed and expected prob-
abilities of the motif. Simply using the observed prob-
ability (relative frequency) of a motif to infer under- or
over-representation is inappropriate. This is because the
observed probability of a motif is not an independent
entity and is influenced by the relative frequencies of its
sub-motifs. For example the observed probability of the
dinucleotide AA might be very high in a sequence, sim-
ply because the sequence has a high proportion of the
mononucleotide A. Therefore AA, despite being fre-
quent, is not over-represented. Thus the observed prob-
abilities of sub-motifs need to be considered when
estimating the expected probability of a motif.
Representation can be defined as a ratio of observed
over expected probabilities. The observed probability
(pobs) of a motif is the total counts of the motif (e.g. AG)
in the sequence divided by the total counts of all other
possible motifs with the same length (AA, AC, AG, . . .,
TT). The expected probability (pexp) of a motif can be
calculated using the observed probabilities of its sub-
motifs [20]. For example the expected probability of the
dinucleotide AG is the product of the observed probabil-
ities of the mononucleotides A and G. Eq. 1 shows
the representation (D) of dinucleotide AG as a typical
example.
D AGð Þ ¼ pobs AGð Þ
pexp AGð Þ ¼
pobs AGð Þ
pobs Að Þ  pobs Gð Þ ð1Þ
The representations of hA3G and/or hA3F target
motifs (GG and GA, respectively) decrease and those of
product motifs (AG and AA, respectively) increase in
hypermutated sequences compared to normal HIV
sequences. We define two ratios of product over target
representations, one for hA3G (Eq. 2) and one for hA3F
(Eq. 3). As will be described later these diagnostic ratios
(DRs hereafter) are used together in a bivariate distribu-
tion to identify hypermutated sequences.
DRhA3G ¼ D AGð ÞD GGð Þ ð2Þ
DRhA3F ¼ D AAð ÞD GAð Þ ð3Þ
The dinucleotide GG is changed to AG by hA3G;
therefore, those HIV sequences that have been targeted
by hA3G are expected to have a higher DRhA3G com-
pared to normal sequences. By the same token, mutation
by hA3F results in an increase in DRhA3F. Sequences that
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show an increase in both DRs. Importantly we do not
measure simply the frequency ratio of AG/GG (for ex-
ample in the case of hA3G). Rather, we find the ratio of
the observed relative frequency of AG to the expected
relative frequency of AG (based on the underlying rela-
tive frequencies of A and G in the sequence) divided by
the ratio of the observed relative frequency of GG to the
expected relative frequency, thus accounting for varia-
tions in base counts between sequences.
We note that this analysis of dinucleotide motifs can
be extended to incorporate longer motifs, and indeed in
our previous work we have studied the motif representa-
tion of dinucleotides, trinucleotides, and tetranucleotides
[20]. However, as the motif preference of hA3F is not
found to extend beyond dinucleotide in the full genome
in vivo HIV-1 sequences (see Figure S1 of the Additional
file 1), we utilise only the dinucleotide motif for both
enzymes. In addition, although factors such as codon
bias and conserved regulatory motifs might affect the
absolute value of the representation of motifs at a popu-
lation level, they do not affect the proposed method
that is based on the ‘difference’ in the representation
of motifs from normal and hypermutated sequences.
That is, we do not require normal sequences to have a
ratio of exactly one, but rather empirically determine
the ‘normal’ range for the ratio, which includes these
factors.
We downloaded 2829 full genome (> 7000 n.t.) HIV-1
sequences from the LANL database as well as 88
sequences identified as “hypermutated” by LANL, in
June 2011. For each sequence we calculated DRhA3G and
DRhA3F and then the Hotelling’s T
2 statistic. The Hotell-
ing’s T2 statistic (Eq. 4) is an extension of the Student
t statistic to multivariate distributions. It is used to de-
termine group membership in data with more than one
measured variable [25].
T2i ¼ xi  xð ÞS1 xi  xð Þ0 ð4Þ
In this work, xi is a vector of length two containing
DRhA3G and DRhA3F of sequence i, x
― is a vector of length
two containing the two averages of 2829 DRhA3G and
DRhA3F from the normal HIV-1 sequences. S is the
variance-covariance matrix.
The Hotelling’s T2 statistic of a given HIV-1 sequence
is the square of the Mahalanobis distance of the se-
quence from the centre of the population of normal
HIV-1 sequences in a two-dimensional space specified
by DRhA3G and DRhA3F. The larger this distance the less
likely the sequence is normal, and therefore the more
likely it is hypermutated. For each sequence, the likeli-
hood of its membership to the normal HIV-1 population
is quantified using the probability associated with its T2statistic [25]. The confidence level (α) of the Hotelling
T2 statistic is given by Eq. 5
T2i ¼
J I  1ð Þ
I  Jð Þ F α; J ; I  Jð Þ ð5Þ
where I is the number of HIV sequences (here 2829), J is
the number of variables (here two, DRhA3G and DRhA3F),
F is the Fisher’s F statistic at the confidence level α and
degrees of freedom J and I-J.
To test the accuracy of the group membership predic-
tion by our proposed method, we performed the same
analysis on 19 HIV-1 sequences mutated in vitro by
hA3G or hA3F [7].
Additional files
Additional file 1: Figure S1. DRhA3G and DRhA3F of preferred
dinucleotide, trinucleotide and tetranucleotide motifs in the normal and
hypermutated HIV-1 sequences. Figure S2. Analysis of the hA3G and
hA3F footprint on the negative strand of the HIV-1 sequences. Table S1.
Details of the HIV-1 sequences identified as hypermutated at > 99.9%
probability level using the proposed method in this paper. Figure S. The
plot of DRhA3G versus DRhA3F for normal HIV-1 subtypes B, C and A1.
Additional file 2: Hypersign. A tool for identification of hypermutated
sequences.
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